MST1 and pancreatic neoplasm: Chakedis et al. recently reported promising results with a small-molecule tyrosine kinase inhibitor that inhibited MSP ligand-mediated RON kinase activation as well as the constitutive kinase activity of RON isoforms, including sfRON, in pancreatic cancer cell lines [37].